Lilly

News mentioning Lilly · Wikidata · RSS

Top stories

1. FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL2 outlets · 2026-10-03 15:22 UTC

Latest

1. FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLLfinanzen.ch · 2026-10-03 15:22 UTC · story
2. Lilly's Foundayo Pill Linked to 57% Lower Predicted Diabetes Risk in ATTAIN-1 Modeling, but No Cases Were Countedmedicaldaily.com · 2026-10-03 02:30 UTC · story
3. Blood cancer first treatment with 'Jypnirka'... Lilly expands US approvalcdn.medipana.com · 2026-10-02 23:11 UTC · story
4. Lilly's Ebglyss Cleared or Nearly Cleared Hand and Foot Eczema in 53% of Patients Versus 27% on Placebomedicaldaily.com · 2026-10-02 20:10 UTC · story
5. Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLprnewswire.com · 2026-10-02 19:30 UTC · story
6. Lilly, Foghorn part ways; Wave's FDA-approved plansbiopharmadive.com · 2026-10-02 16:25 UTC · story
7. Foghorn downgraded at TD Cowen on Lilly exit (FHTX:NASDAQ)seekingalpha.com · 2026-10-02 14:08 UTC · story
8. STAT+: Lilly bypasses Australian pharmacies with DTC modelstatnews.com · 2026-10-02 13:58 UTC · story
   
9. Lilly's Eloralintide Plus Tirzepatide Produced 23.3% Weight Loss in Phase 2 Trial of Adults with Type 2 Diabetesmedicaldaily.com · 2026-10-02 03:51 UTC · story
10. Lilly's Foundayo Pill Matched Insulin on Heart Safety in Lancet Trial, but Its Lower Death Rate Needs Cautionmedicaldaily.com · 2026-10-02 03:22 UTC · story
11. India has biotech talent and know-how, but funding ecosystem lags: Lilly CEOindiatimes.com · 2026-10-02 00:45 UTC · story
12. Recon: Sanofi, Regeneron expand partnership after Dupixent success; Lilly amylin-Zepbound combo succeeds in mid-stage trialraps.org · 2026-10-01 19:50 UTC · story
13. Foundayo Pill Edged Higher-Dose Oral Semaglutide on Weight and A1C in Lilly's Indirect Type 2 Diabetes Analysismedicaldaily.com · 2026-10-01 01:24 UTC · 1 more reports
14. Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trialfinanzen.ch · 2026-09-30 15:42 UTC · story
15. Lilly's experimental combination outperforms Zepbound in weight loss studypox.globo.com · 2026-09-30 15:12 UTC · 1 more reports
    
16. People With Type 2 Diabetes Lost up to 60 Pounds on Lilly's Latest Weight Loss Drugtoday.com · 2026-09-30 14:41 UTC · 8 more reports
17. Lilly sets up next-gen obesity battle with full phase 3 retatrutide datafiercebiotech.com · 2026-09-30 09:56 UTC · story
18. Lilly's Retatrutide Drives Significant Weight Loss And A1C Improvement In Phase 3 Diabetes Studyrttnews.com · 2026-09-30 05:00 UTC · 1 more reports
19. Obesity and diabetes drug dominance battle... Novo and Lilly argue figures to claim company superioritycdn.pharmnews.com · 2026-09-30 00:22 UTC · story
20. Lilly says Zepbound tops Novo's Wegovy HD (LLY:NYSE)seekingalpha.com · 2026-09-29 12:39 UTC · story
21. Lilly surpasses Novo: Beats Novo's strongest drugborsen.dk · 2026-09-29 11:01 UTC · story
    
22. Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?insidermonkey.com · 2026-09-28 20:08 UTC · story
23. Lilly pushes an initiative to bring its obesity and diabetes treatments to low-income countriesinfosalus.com · 2026-09-28 16:07 UTC · story
    
24. Lilly gets FDA approval for severe alopecia areata treatment for paediatric patientspmlive.com · 2026-09-28 11:59 UTC · 1 more reports
25. US approves once-daily insulin by Lillybosa.co.kr · 2026-09-28 00:32 UTC · story
26. FDA approves 'Olumiant' by Lilly for the treatment of severe alopecia areata in adolescents aged 12 and overcdn.pharmnews.com · 2026-09-27 23:51 UTC · story